Company Filing History:
Years Active: 2014-2019
Title: Yongbo Liu: Innovator in Pharmaceutical Chemistry
Introduction
Yongbo Liu is a notable inventor based in Shanghai, China, recognized for his contributions to pharmaceutical chemistry. With a total of four patents under his name, he has made significant advancements in the synthesis of compounds that play a crucial role in various therapeutic applications, particularly in oncology.
Latest Patents
Yongbo Liu's latest patents include a remarkable invention related to a specific compound, known as (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt. This patent covers not only the crystalline forms of this compound but also the methods for its preparation. The pharmaceutical compositions derived from this compound are significant as they have potential applications in treating various diseases and conditions, including multiple types of cancer. In addition, he has developed processes for synthesizing dihydropyridophthalazinone derivatives, notable for their role as potent poly(ADP-ribose)polymerase (PARP) inhibitors.
Career Highlights
Throughout his career, Yongbo Liu has worked with respected organizations such as Biomarin Pharmaceutical Inc. and Medivation Technologies, Inc. His work at these companies has allowed him to contribute to innovative projects that push the boundaries of pharmaceutical development. His expertise in medicinal chemistry has positioned him as a significant figure in the field.
Collaborations
In addition to his individual achievements, Yongbo Liu has collaborated with esteemed colleagues in the industry, including Bing Wang and Daniel T Chu. These partnerships have been instrumental in enhancing the research and development initiatives within the pharmaceutical sector, fostering advancements that can lead to effective treatments for complex diseases.
Conclusion
Yongbo Liu's contributions to pharmaceutical chemistry demonstrate his innovative spirit and dedication to improving healthcare outcomes. With a growing portfolio of patents and a history of collaboration with prominent companies and professionals, he continues to be a valuable asset in the field of drug development, paving the way for improved therapeutic options for patients worldwide.